News | March 08, 2022
Moderna to set up first mRNA facility in Kenya
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent
Adds to Merck’s growing global, multi-modality CDMO network, following newly formed CDMO business unit in Life Science
The transaction is expected to close in the first quarter of 2022
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
Up to 100 million mRNA vaccine doses could be produced in Australia each year
The aim is to first produce Covid-19 vaccines and then add more vaccines in the years to come
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
Subscribe To Our Newsletter & Stay Updated
